1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology
20. März 2023 08:00 ET | Timber Pharmaceuticals
- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis - BASKING...